Roche’s Ocrevus SC (Ocrelizumab) Receives the EC’s Approval to Treat Multiple Sclerosis
Shots:
- EC has granted approval to the SC formulation of Ocrevus for treating relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) based on P-III (OCARINA II)
- OCARINA II trial assessing clinical & radiological efficacy, safety as well as PK profile of Ocrevus’ SC vs IV formulation among RMS or PPMS patients (n=236). Study showed superiority of SC vs IV on the basis of its levels in the blood with similar control of clinical relapses and MRI lesions; safety profile aligned with the IV formulation
- Ocrevus SC is an HCP administered formulation and developed as addition to IV formulation. SC formulation has been developed using Halozyme's ENHANZE proprietary technology
Ref: Roche | Image: Roche
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
